Rating Change
Roth Capital analysts initiated coverage on Annovis Bio, Inc. (NYSE:ANVS) with a Buy rating on July 08, 2026.
Rating Change Roth Capital analysts initiated coverage on Annovis Bio, Inc. (NYSE:ANVS) with a Buy rating on July 08, 2026. Market Context Annovis Bio, Inc.

Roth Capital analysts initiated coverage on Annovis Bio, Inc. (NYSE:ANVS) with a Buy rating on July 08, 2026.
Annovis Bio, Inc. operates in the Healthcare sector. The stock currently trades at $1.94 with a market capitalization of $52.7M. The stock has declined 18.6% over the past 52 weeks.
Analyst coverage from Roth Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Annovis Bio, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 08, 2026 | Roth Capital | Buy | N/A |
| Apr 14, 2026 | Canaccord Genuity | Buy | N/A |
| Sep 30, 2025 | Canaccord Genuity | Buy | N/A |
| Sep 03, 2025 | HC Wainwright & Co. | Buy | N/A |
| Jun 09, 2025 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ANVS Stock Page
A Buy rating from Roth Capital reflects the analyst's outlook on Annovis Bio, Inc. (NYSE:ANVS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ANVS forecast page.
Current market data
NYSE · ANVS
$1.19
Down: -$0.03 · -2.46%
Live quote updated
Keep reading